Logo
Logo

About Levocetirizine Dihydrochloride API

Product
  • Therapeutic CategoryRespiratory

  • CAS Number

    130018-87-0

  • API Technology

    Synthetic

  • Dose Form

    Solution/Tablet

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF, EUDMF, Korea DMF, CEP Submitted

Mechanism of Action

Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.

Indication

XYZAL is a histamine H1-receptor antagonist indicated for:

  • The relief of symptoms associated with perennial allergic rhinitis
  • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria

Related APIs

Cetirizine Dihydrochloride

Respiratory

arrow

Desloratadine

Respiratory

arrow

Fexofenadine Hydrochloride (Form 1)

Respiratory

arrow

Levocetirizine Dihydrochloride

Respiratory

arrow

Montelukast Sodium

Respiratory

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.